{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:59:20Z","timestamp":1793314760441,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81673306"],"award-info":[{"award-number":["81673306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81703348"],"award-info":[{"award-number":["81703348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81874289"],"award-info":[{"award-number":["81874289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u201cDouble First-Class\u201d University project","award":["CPU2018GY04"],"award-info":[{"award-number":["CPU2018GY04"]}]},{"name":"\u201cDouble First-Class\u201d University project","award":["CPU2018GY35"],"award-info":[{"award-number":["CPU2018GY35"]}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejmech.2018.11.011","type":"journal-article","created":{"date-parts":[[2018,11,11]],"date-time":"2018-11-11T01:11:31Z","timestamp":1541898691000},"page":"212-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Small molecules as inhibitors of PCSK9: Current status and future challenges"],"prefix":"10.1016","volume":"162","author":[{"given":"Shengtao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-0402","authenticated-orcid":false,"given":"Jinyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.11.011_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016","volume":"390","author":"C.G","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.11.011_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.ejmech.2018.11.011_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","article-title":"A\u00a0review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","volume":"10","author":"Wadhera","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.11.011_bib5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib7","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2018.11.011_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib9","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib17","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2018.11.011_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.ejmech.2018.11.011_bib19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bmcl.2018.02.046","article-title":"Small molecule modulators of PCSK9-a literature and patent overview","volume":"28","author":"Pettersen","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.11.011_bib20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.11.011_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMra1106700","article-title":"Proprotein convertases in health and disease","volume":"365","author":"Artenstein","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib22","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","article-title":"Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein","volume":"286","author":"Du","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2018.11.011_bib24","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.011_bib26","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.11.011_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2018.11.011_bib28","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.11.011_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A\u00a0receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.11.011_bib30","doi-asserted-by":"crossref","first-page":"40965","DOI":"10.1074\/jbc.M110.154815","article-title":"Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events","volume":"285","author":"Benjannet","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib32","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","article-title":"New developments in proprotein convertase subtilisin\u2013kexin 9's biology and clinical implications","volume":"27","author":"Seidah","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib34","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Lambert","year":"2012","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2018.11.011_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrd.2017.83","article-title":"Nine paths to PCSK9 inhibition","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.011_bib37","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in hight-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib38","first-page":"1360","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study","volume":"37","author":"Kastelein","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11095-016-2054-6","article-title":"Population pharmacokinetics (PK) and pharmacodynamics (PD) analysis of LY3015014, a monoclonal antibody to protein convertase subtilisin\/kexin type 9 (PCSK9) in healthy subjects and hypercholesterolemia patients","volume":"34","author":"Shen","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib40","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR Study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/clc.22687","article-title":"A\u00a0phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9","volume":"40","author":"Baruch","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib42","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib43","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial, Brit","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib44","unstructured":"Safety Study of BMS-844421 for Treatment of Hypercholesterolemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01082562?term=BMS-844421&rank=1."},{"key":"10.1016\/j.ejmech.2018.11.011_bib45","unstructured":"A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03427710?term=Civi-007&rank=1."},{"key":"10.1016\/j.ejmech.2018.11.011_bib46","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.11.011_bib49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/jpet.117.246652","article-title":"Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin\/kexin type 9 (PCSK9) antibodies, DS-9001a, albumin binding domain-fused anticalin protein","volume":"365","author":"Masuda","year":"2018","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.11.011_bib50","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2018.11.011_bib51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in\u00a0vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.11.011_bib53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in\u00a0vivo-brief report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A\u00a0non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in\u00a0vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib55","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/d41586-018-02482-4","article-title":"A\u00a0CRISPR edit for heart disease","volume":"555","author":"King","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.11.011_bib56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.tibs.2017.04.008","article-title":"Inhibiting translation one protein at a time","volume":"42","author":"Disney","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2018.11.011_bib57","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.chembiol.2016.08.016","article-title":"A\u00a0small-molecule anti-secretagogue of PCSK9 targets the 80S ribosome to inhibit PCSK9 protein translation","volume":"23","author":"Petersen","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib58","series-title":"N-piperidin-3-ylbenzamide Derivatives for Treating Cardiovascular Diseases","author":"Darout","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001882","article-title":"Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain","volume":"15","author":"Lintner","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.chembiol.2015.11.012","article-title":"New insights into the biosynthetic logic of ribosomally synthesized and post-translationally modified peptide natural products","volume":"23","author":"Ortega","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.21327","article-title":"Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications","volume":"35","author":"Wang","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.11.011_bib62","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1002\/anie.201708744","article-title":"Liver-targeted small-molecule inhibitors of proprotein convertase subtilisin\/kexin type 9 synthesis","volume":"56","author":"McClure","year":"2017","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.11.011_bib63","series-title":"Substituted Amide Compounds","author":"Darout","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17460441.2013.748744","article-title":"Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes","volume":"8","author":"Pfefferkorn","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.011_bib65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bmcl.2018.02.035","article-title":"Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1","volume":"28","author":"Takahashi","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.11.011_bib66","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1021\/acs.jmedchem.8b00650","article-title":"Small molecule proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: hit to lead optimization of systemic agents","volume":"61","author":"Londregan","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib67","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.biochem.74.082803.133130","article-title":"Antibiotics targeting ribosomes: resistance, selectivity, synergism, and cellular regulation","volume":"74","author":"Yonath","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib68","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.11.011_bib70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2016.09.004","article-title":"The heparanase\/heparan sulfate proteoglycan axis: a potential new therapeutic target in sarcomas","volume":"382","author":"Cassinelli","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2018.11.011_bib71","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM198810273191710","article-title":"Heparin for prevention of atherosclerosis","volume":"319","author":"Shulman","year":"1988","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib72","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(87)90291-1","article-title":"Effectiveness of low-dose heparin in prevention of myocardial reinfarction","volume":"329","author":"Serneri","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.11.011_bib73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.CIR.13.4.489","article-title":"A\u00a0controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis","volume":"13","author":"Engelberg","year":"1956","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2018.11.011_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0954-6820.1967.tb11519.x","article-title":"Long-term heparin treatment in ischaemic heart disease","volume":"182","author":"B\u00f6ttiger","year":"1967","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib75","first-page":"141","article-title":"Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units\/day) in the treatment of patients with acute coronary event-first year and long-term comparative mortality","volume":"94","author":"Sayen","year":"1983","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.ejmech.2018.11.011_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexcr.2018.03.013","article-title":"Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells","volume":"366","author":"Yang","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib77","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3349\/ymj.2015.56.5.1251","article-title":"In silico screening of chemical libraries to develop inhibitors that hamper the interaction of PCSK9 with the LDL receptor","volume":"56","author":"Min","year":"2015","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ejmech.2018.11.011_bib78","series-title":"Composition for Preventing and Treating Cholesterol-related Diseases","author":"Park","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib79","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ejmech.2015.01.022","article-title":"LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation","volume":"92","author":"Alghamdi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib80","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1002\/anie.201412070","article-title":"Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes","volume":"54","author":"Pelay-Gimeno","year":"2015","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.11.011_bib81","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2018.11.011_bib82","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1039\/C6OB01642A","article-title":"Disrupting the PCSK9\/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic","volume":"14","author":"Stucchi","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib83","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/ja1071916","article-title":"Universal peptidomimetics","volume":"133","author":"Ko","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.11.011_bib84","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/jacs.7b09360","article-title":"Small molecule inhibitors of the PCSK9\u00b7 LDLR interaction","volume":"140","author":"Taechalertpaisarn","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.11.011_bib85","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1021\/ja3067258","article-title":"Exploring key orientations at protein-protein interfaces with small molecule probes","volume":"135","author":"Ko","year":"2012","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.11.011_bib86","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1039\/C4SC01295J","article-title":"Small molecule probes that perturb a protein-protein interface in antithrombin","volume":"5","author":"Xin","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2018.11.011_bib87","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.nut.2016.04.007","article-title":"Lipid-modifying effects of nutraceuticals: an evidence-based approach","volume":"32","author":"Sahebkar","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.ejmech.2018.11.011_bib88","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1021\/acs.jmedchem.5b01566","article-title":"Synthesis and biological evaluation of novel Bouchardatine derivatives as Potential Adipogenesis\/lipogenesis inhibitors for Antiobesity treatment","volume":"58","author":"Rao","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","article-title":"Regulation of PCSK9 by nutraceuticals","volume":"120","author":"Momtazi","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejmech.2017.09.020","article-title":"Lipid lowering agents of natural origin: an account of some promising chemotypes","volume":"140","author":"Singh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib91","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ptr.2399","article-title":"Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine","volume":"22","author":"Imanshahidi","year":"2008","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib92","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.metabol.2008.01.037","article-title":"Combination of simvastatin with berberine improves the lipid-lowering efficacy","volume":"57","author":"Kong","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2018.11.011_bib93","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0032-1328321","article-title":"The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials","volume":"79","author":"Dong","year":"2013","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib94","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2018.11.011_bib96","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1\u03b1 plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib97","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/14786410802496911","article-title":"Acetylcholinesterase inhibitors from Corydalis yanhusuo","volume":"25","author":"Xiao","year":"2011","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jep.2007.05.006","article-title":"Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort","volume":"113","author":"Adsersen","year":"2007","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib99","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/10286020.2017.1386658","article-title":"Corydaline inhibits enterovirus 71 replication by regulating COX-2 expression","volume":"19","author":"Wang","year":"2017","journal-title":"J.\u00a0Asian Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib100","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1080\/13880209.2016.1211714","article-title":"Simultaneous screening and analysis of antiplatelet aggregation active alkaloids from Rhizoma Corydalis","volume":"54","author":"Zhang","year":"2016","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib101","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4014\/jmb.1707.07009","article-title":"In\u00a0vivo disease control efficacy of isoquinoline alkaloids isolated from Corydalis ternata against wheat leaf rust and pepper anthracnose","volume":"28","author":"Han","year":"2017","journal-title":"J.\u00a0Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib102","series-title":"Berberine Derivatives Useful for Modulating Lipid Levels and Their Methods of Synthesis","author":"Liu","year":"2011"},{"key":"10.1016\/j.ejmech.2018.11.011_bib103","series-title":"Carydaline Derivatives Useful for Reducing Lipid Levels","author":"Liu","year":"2010"},{"key":"10.1016\/j.ejmech.2018.11.011_bib104","unstructured":"http:\/\/www.chinadrugtrials.org.cn\/No. CTR20160744."},{"key":"10.1016\/j.ejmech.2018.11.011_bib105","series-title":"Phenyl [a]indole[2,3-g]quinolizine Compounds, Preparation Method Therefor, Pharmaceutical Composition, and Applications Thereof","author":"Liu","year":"2017"},{"key":"10.1016\/j.ejmech.2018.11.011_bib106","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/jf073105v","article-title":"Extraction, processing, and storage effects on curcuminoids and oleoresin yields from Curcuma longa L. grown in Jamaica","volume":"56","author":"Green","year":"2008","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib107","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bph.13621","article-title":"Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases","volume":"174","author":"Kunnumakkara","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib108","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ptr.5197","article-title":"Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Yang","year":"2014","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib109","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ptr.5201","article-title":"Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus","volume":"28","author":"Neerati","year":"2014","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2018.11.011_bib110","first-page":"825","article-title":"PCSK9\/LDLR pathway mediates curcumin trinicotinate promoting lipid uptake of HepG2","volume":"42","author":"Ping","year":"2015","journal-title":"Prog. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2018.11.011_bib111","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin: miniperspective","volume":"60","author":"Nelson","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib112","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1039\/b514045p","article-title":"An update on bioactive plant lignans","volume":"22","author":"Saleem","year":"2005","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2018.11.011_bib113","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phytochem.2017.01.010","article-title":"Lignans from the fruits of Schisandra chinensis (Turcz.) Baill inhibit proprotein convertase subtilisin\/kexin type 9 expression","volume":"136","author":"Pel","year":"2017","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ejmech.2018.11.011_bib114","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2147\/TCRM.S144121","article-title":"Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9","volume":"13","author":"Adorni","year":"2017","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2018.11.011_bib115","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1021\/acs.jafc.7b03614","article-title":"The mulberry (Morus alba L.) fruit a review of characteristic components and health benefits","volume":"65","author":"Yuan","year":"2017","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib116","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1021\/acs.jafc.7b02088","article-title":"Chemical constituents with proprotein convertase subtilisin\/kexin type 9 mRNA expression inhibitory activity from dried immature Morus alba fruits","volume":"65","author":"Pel","year":"2017","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2014.09.047","article-title":"Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway","volume":"745","author":"Hao","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib118","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-015-0325-x","article-title":"Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"15","author":"Wang","year":"2016","journal-title":"Cardiovasc. Diabetologe"},{"key":"10.1016\/j.ejmech.2018.11.011_bib119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.041","article-title":"Cardiovascular actions and therapeutic potential of tanshinone IIA","volume":"220","author":"Gao","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2018.11.011_bib120","article-title":"Tanshinone IIA modulates low density lipoprotein uptake via down-regulation of PCSK9 gene expression in HepG2 Cells","volume":"11","author":"Chen","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2018.11.011_bib121","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.3892\/mmr.2016.5133","article-title":"Effects of Tanshinone IIA on the modulation of miR-33a and the SREBP-2\/Pcsk9 signaling pathway in hyperlipidemic rats","volume":"13","author":"Jia","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2018.11.011_bib122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1248\/bpb.32.259","article-title":"Anti-angiogenic and anti-metastatic effects of \u03b2-1, 3-D-glucan purified from Hanabiratake, Sparassis crispa","volume":"32","author":"Yamamoto","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2018.11.011_bib123","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1021\/acs.jafc.7b02657","article-title":"New aromatic compounds from the fruiting body of Sparassis crispa (wulf.) and their inhibitory activities on proprotein convertase subtilisin\/kexin type 9 mRNA expression","volume":"65","author":"Bang","year":"2017","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib124","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/molecules23020504","article-title":"Discovery of flavonoids from Scutellaria baicalensis with inhibitory activity against PCSK 9 expression: isolation, synthesis and their biological evaluation","volume":"23","author":"Nhoek","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.11.011_bib125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/nu8030167","article-title":"Quercetin, inflammation and immunity","volume":"8","author":"Li","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2018.11.011_bib126","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ejmech.2018.06.053","article-title":"Therapeutic potential of quercetin as a cardiovascular agent","volume":"155","author":"Patel","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib127","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","article-title":"Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin\/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture","volume":"4","author":"Mbikay","year":"2014","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2018.11.011_bib128","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1021\/acs.jafc.8b02559","article-title":"Pinostrobin inhibits proprotein convertase subtilisin\/kexin-type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells","volume":"66","author":"Gao","year":"2018","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib129","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jafc.8b02696","article-title":"Naringin activates AMPK resulting in altered expression of SREBPs, PCSK9, and LDLR to reduce body weight in obese C57BL\/6J mice","author":"Sui","year":"2018","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jep.2011.06.041","article-title":"Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in\u00a0vivo and in\u00a0vitro","volume":"137","author":"Chong","year":"2011","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-511X-13-35","article-title":"Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats","volume":"13","author":"Zhang","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejmech.2018.11.011_bib132","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11655-014-1846-y","article-title":"Short-and long-term effects of Xuezhikang (\u8840\u8102\u5eb7), an extract of cholestin, on serum proprotein convertase subtilisin\/kexin type 9 levels","volume":"22","author":"Jia","year":"2016","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.ejmech.2018.11.011_bib133","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jcpt.12374","article-title":"Systematic review of red yeast rice compared with simvastatin in dyslipidaemia","volume":"41","author":"Ong","year":"2016","journal-title":"J.\u00a0Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejmech.2018.11.011_bib134","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vph.2015.07.001","article-title":"Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre-and postmenopausal women: a randomised study","volume":"76","author":"Graversen","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/13543776.2016.1206080","article-title":"Proprotein convertase subtilisin\/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","volume":"26","author":"Elbitar","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.11.011_bib136","series-title":"Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity","author":"Barta","year":"2017"},{"key":"10.1016\/j.ejmech.2018.11.011_bib137","series-title":"Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity","author":"Barta","year":"2017"},{"key":"10.1016\/j.ejmech.2018.11.011_bib138","series-title":"Phenylpiperazine Proprotein Convertase Subtilisin\/kexin Type 9 (PCSK9) Modulators and Their Use","author":"Barta","year":"2017"},{"key":"10.1016\/j.ejmech.2018.11.011_bib139","series-title":"Anti-proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment And\/or Prevention of Cardiovascular Diseases","author":"Abdel-Meguid","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib140","series-title":"Anti-PCSK9 Compounds and Methods for the Treatment And\/or Prevention of Cardiovascular Diseases","author":"Abdel-Meguid","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib141","series-title":"Anti-proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment And\/or Prevention of Cardiovascular Diseases","author":"Abdel-Meguid","year":"2017"},{"key":"10.1016\/j.ejmech.2018.11.011_bib142","series-title":"PCSK9 Inhibitors and Methods of Use Thereof","author":"Abou-Gharbia","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib143","series-title":"Proprotein Convertase Subtilisin\/kexin Type 9 (PCSK9) Allosteric Binding Ligands to Modulate Serum Low Density Lipoprotein (LDL) Levels","author":"Muehlemann","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib144","series-title":"Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin\/kexin Type 9 (PCSK9) Protein Activity","author":"Barta","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib145","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem. Biol. (Lond.)"},{"key":"10.1016\/j.ejmech.2018.11.011_bib146","series-title":"Methods and Compositions for Reducing PCSK9 Expression","author":"Scharfmann","year":"2018"},{"key":"10.1016\/j.ejmech.2018.11.011_bib147","series-title":"Methods of Lowering Proprotein Convertase Subtilisin\/kexin Type 9 (PCSK9)","author":"Milne","year":"2013"},{"key":"10.1016\/j.ejmech.2018.11.011_bib148","series-title":"Fatty Acid Niacin Conjugates","author":"Jirousek","year":"2015"},{"key":"10.1016\/j.ejmech.2018.11.011_bib149","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/acs.jmedchem.5b01961","article-title":"Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid","volume":"59","author":"Vu","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib150","series-title":"Substituted Nitrogen-containing Heterocyclic Derivatives and Applications Thereof","author":"Li","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib151","series-title":"Substituted Nitrogen Heterocyclic Derivatives and Use Thereof","author":"Li","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib152","series-title":"Modulators of Hepatic Lipoprotein Metabolism","author":"Nagiec","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib153","series-title":"Modulators of Hepatic Lipoprotein Metabolism","author":"Nagiec","year":"2016"},{"key":"10.1016\/j.ejmech.2018.11.011_bib154","series-title":"Small Molecule Modulators of PCSK9 and Methods of Use Thereof","author":"Guay","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib155","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/tx400032n","article-title":"Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation","volume":"26","author":"Li","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib156","series-title":"Compounds for the Treatment of Dyslipidemia and Related Diseases","author":"Pingali","year":"2011"},{"key":"10.1016\/j.ejmech.2018.11.011_bib157","series-title":"Heterocyclic Compounds Suitable for the Treatment of Dyslipidemia","author":"Pingali","year":"2012"},{"key":"10.1016\/j.ejmech.2018.11.011_bib158","series-title":"Novel Compounds for the Treatment of Dyslipidemia and Related Diseases","author":"Pingali","year":"2013"},{"key":"10.1016\/j.ejmech.2018.11.011_bib159","series-title":"Compounds for the Treatment of Dyslipidemia and Other Diseases","author":"Pingali","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib160","series-title":"Novel Compounds for the Treatment of Dyslipidemia and Related Diseases","author":"Pingali","year":"2014"},{"key":"10.1016\/j.ejmech.2018.11.011_bib161","series-title":"Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline Molecules as PCSK9 Allosteric Binders","author":"Imbriglio","year":"2018"},{"key":"10.1016\/j.ejmech.2018.11.011_bib162","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nsmb.3453","article-title":"Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib163","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.011_bib164","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.011_bib165","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1073\/pnas.1615475114","article-title":"Selection of DNA aptamers with two modified bases","volume":"114","author":"Gawande","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.11.011_bib166","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41557-018-0008-9","article-title":"Evolution of sequence-defined highly functionalized nucleic acid polymers","volume":"10","author":"Chen","year":"2018","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib167","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2018.11.011_bib168","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in\u00a0vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib169","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib170","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","article-title":"New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism","volume":"309","author":"Miyosawa","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2018.11.011_bib171","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.celrep.2015.11.006","article-title":"GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation","volume":"13","author":"Poirier","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2018.11.011_bib172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169761","article-title":"Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives","volume":"12","author":"Arrieta","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2018.11.011_bib173","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2017.10.080","article-title":"Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease","volume":"253","author":"Stam-Slob","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib174","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/clc.22924","article-title":"PCSK9 inhibitor valuation: a science-based review of the two recent models","volume":"41","author":"Baum","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejmech.2018.11.011_bib175","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.11.011_bib176","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein-protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:51:43Z","timestamp":1759326703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418309656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":176,"alternative-id":["S0223523418309656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.011","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecules as inhibitors of PCSK9: Current status and future challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}